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Ferrous sulphate does not directly affect pteroylmonoglutamic 
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A variety of compounds whicb bind to Fe have substantial reductions in absorption when co-administered 
with Fe compounds. The bidding of both Fez+ and Fe3+ ions to pteroylmonoglutamic acid and the 
pteroylmonoglutamate dianion was examined in vitro. In dimethylsulphoxide (DMSO) alone, 
pteroylmonoglutamate formed a 2 : 1 @teroylmonoglutamate: Fe3+ ion) complex. However, in 
DMSO-aqueous Bis-Tris buffer (4:1, v/v; pH 60)  no evidence of complex formation could be seen. 
Likewise spectroscopic evidence was obtained for complex formation with Fez+ ion and pteroylmono- 
glutamate in DMSO alone but not in the aqueous DMSO buffer. In vivo studies examined the effect of 
FeSO, on pteroylmonoglutamic acid absorption in an isolated perfused rat jejunal model of nutrient 
absorption. The dose of pteroylmonoglutamic acid approximated a human dose of 1 mg for the rat, while 
the FeSO, doses were chosen to represent 6*4mg, 64mg and 300mg human doses. There was no 
significant effect of FeSO, on pteroylmonoglutamic acid absorption or instability of pteroylmonoglutamic 
acid in vivo in the presence of FeSO, in the rat. Although 2: 1 binding of pteroylmonoglutamic acid to 
Fe ions could be demonstrated in DMSO alone, no binding could be demonstrated in DMSO-Bis-Tris 
buffer (4: 1, v/v; pH 6.0). It is unlikely that there will be a significant reduction in pteroylmonoglutamic 
acid absorption during concurrent ingestion of Fe preparations. 
Drug-nutrient interaction : Nutrient-nutrient interaction: Iron : Pteroylmonoglutamic acid: Complex 
formation 
Several compounds such as thyroxine L-dioxyphenylalanine (L-dopa), methyldopa, 
penicillamine, tetracycline and quinolone antimicrobials which bind to Fe have reduced 
absorption, blood levels or clinical effect when concurrently ingested with Fe supplements 
(Campbell & Hasinoff, 1991 ; Campbell et  al. 1992a, b). Pteroylmonoglutamic acid 
supplements are frequently prescribed (Hillman, 1990) and are recommended to be used by 
women before and during pregnancy to prevent neural tube defects in the fetus (Czeizel & 
Dudas, 1992; Rosenberg, 1992). Fe-replacement therapy is also common (La Piana 
Simonsen, 1990) and Fe is taken in over-the-counter preparations by many patients. Many 
multivitamin and mineral preparations contain both Fe and pteroylmonoglutamic acid 
(Canadian Pharmaceutical Association, 1992). Concurrent ingestion of pteroylmono- 
glutamic acid and Fe is therefore likely to be common. Deficiency of Fe predisposes to 
pteroylmonoglutamate deficiency further increasing the likelihood of concurrent therapy 
(Vitale et  al. 1966). Pteroylmonoglutamic acid forms complexes with a variety of metal ions 
including Fez+ (Albert, 1953; Cape et al. 1974; Roos & Williams, 1977), Cu2+ (Albert, 
1953), Zn2+ and Mn2+ (Roos & Williams, 1977) usually with the formation of 2 : l  
(pteroylmonoglutamate :metal) complexes (Albert, 1953 ; Roos & Williams, 1977). From 
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the stability constant of the complex of Fez+ (pteroylmonoglutamate), of log K, = 7.9, at 
pH 7, approximately 46 % of pteroylmonoglutamic acid would be present in the form of an 
Fe2+ complex. Thus, pteroylmonoglutamic acid forms a moderately strong complex with 
Fez+, and these results suggest that an interaction between pteroylmonoglutamic acid and 
Fez+ might occur in vivo (Campbell & Hasinoff, 1991). Hence, it was decided to look for 
observable complex formation of both Fe2+ and Fe3+ ions with pteroylmonoglutamic acid 
under conditions more closely resembling those that might be obtained in vivo and to 
determine the effect of FeSO, on pteroylmonoglutamic acid absorption in an isolated 
perfused rat jejunal model of nutrient/drug absorption. 
M A T E R I A L S  A N D  METHODS 
Pteroylmonoglutamic acid absorption was assessed using a standard rat model of nutrient 
absorption (Meddings & Westergaard, 1989; Campbell et al. 1993a, b). The study was 
approved by the Animal Care Committee of the University of Calgary. Groups of six to 
ten male Sprague Dawley rats (Charles River Canada Inc., St-Constant, Quebec, Canada) 
weighing 23 1-3 12 g were used in the control group and in the experimental groups. The rats 
were anaesthetized using intraperitoneal urethane at approximately 1.25 g/kg. Through a 
mid-line incision immediately distal to the ligament of Treitz, a jejunal segment 
approximately 50 cm in length was isolated with sutures. Catheters were inserted into the 
segment proximally and distally and tied in place. The segments were perfused with 30 ml 
recycling buffer at 37”. The initial buffer consisted of 120 mM-NaC1 and 50 mM-Bis-Tris 
(pH 60). After 30 min, 25 ml buffer was perfused which contained pteroylmonoglutamic 
acid (8.1 ymolll), [3H]pteroylmonoglutamic acid (1.4-2-5 nmol/l), and [14C]polyethylene 
glycol 4000 (4.2 pg/l) with or without FeSO,. The dose of pteroylmonoglutamic acid in the 
rat was chosen to approximate a human dose of 1 mg on a mg/kg basis for the rat 
assuming: a 70 kg person, a 0.25 kg rat and that the total dose was in 10 cm bowel of rat 
intestine (1 ml) at all times. The concentrations of FeSO, used were 6.7, 1.43 and 
0.143 mmol/l and approximated 300,64 and 6.4 mg human doses on a mg/kg basis for the 
rat using the same assumptions as for pteroylmonoglutamic acid. Lumen contents were 
sampled every 10 min for 1 h and were analysed in triplicate in a scintillation counter. 
Pteroylmonoglutamic acid concentrations were calculated by multiplying the original 
pteroylmonoglutamic acid concentration by the Bq,/Bq, of [3H] and were corrected for 
water absorption and secretion by multiplying the pteroylmonoglutamic acid concentration 
by Bq,/Bq, of [14C]polyethylene glycol (Bq, is the activity of [3H] or [“CC] at the start of the 
experiment and Bq, is the activity at a given time x). Absorption rates were calculated from 
the slope of the linear regression line derived from the pteroylmonoglutamic acid 
concentration v. time data between 10 and 60 min, were corrected for length of the bowel 
and are expressed in pmol/cm per min. 
The stability of pteroylmonoglutamic acid was assessed before perfusion and following 
perfusion in bowel segments from two animals in each group by HPLC. The HPLC system 
consisted of a Bio-Rad HPLC pump (model 1330) and a Bio-Rad Biosil ODS 10 reversed 
phase column (Bio-Rad Laboratories Ltd., Mississanga, Ontario, Canada) heated to 35”. 
The mobile phase was 0.01 M-triethylammonium phosphate (pH 6.6) with 125 ml 
methanol/l solvent. One-minute fractions of HPLC solvent were collected and analysed by 
scintillation counting. Pteroylmonoglutamic acid eluted in the 46 min fractions with the 
mobile phase run at 1-0 ml/min. The in vivo stability of pteroylmonoglutamic acid in 
experiments was determined by dividing the percentage of radioactivity eluting under the 
pteroylmonoglutamic acid peak following perfusion in animals by the percentage of 
radioactivity eluting under the pteroylmonoglutamic acid peak before perfusion. 
available at https:/www.cambridge.org/core/terms. https://doi.org/10.1079/BJN19940046
Downloaded from https:/www.cambridge.org/core. University of Basel Library, on 10 Jul 2017 at 15:58:32, subject to the Cambridge Core terms of use,
I R O N - P T E R O Y L M O N O G L U T A M I C  ACID INTERACTION 449 
0.14 
0.12 
0.10 
0) 
0 
$ 0.08 
f! 
8 
9 0-06 
0.04 
0.02 
0.00 
450 500 550 600 
Wavelength (nm) 
Fig. 1. (A) The visible spectrum of 0.6 mmol FeCIJl (bottom); 1.0 mmol pteroylmonoglutamate/I (middle); and 
a mixture of 0.5 mmol FeCIJ and 1.0 mmol pteroylmonoglutamate/l (top) in dimethylsulphoxide (DMSO) 
alone. The spectrum of the mixture displayed a new shoulder at 475nm due to formation of a 2 : l  
(pteroylmonoglutamate: Feat) complex. (B) The legend and conditions are as above, except that pteroylmono- 
glutamic acid was used instead of pteroylmonoglutamate, and the solvent was DMSO-aqueous Bis-Tris buffer 
(4: 1, v/v; pH 6.0). The sum of the spectrum of pteroylmonoglutamic acid and FeCI, alone is very similar to that 
of the mixture, which indicates that no observable complex formation occurs. 
To characterize the binding of pteroylmonoglutamic acid to Fe, a number of 
spectrophotometric experiments were carried out in 1 cm cells on a Cary 1 double beam 
spectrophotometer with its cell compartment maintained at 25". Due to the low solubility 
of pteroylmonoglutamic acid in aqueous buffers, complex formation was looked for in 
either dimethylsulphoxide (DMS0)-aqueous Bis-Tris buffer (4: 1, v/v; pH 6.0) or DMSO 
alone as indicated. The pteroylmonoglutamate dianion was prepared by dissolving 
pteroylmonoglutamic acid in DMSO and adding 2 mol aqueous 5 M-NaOH/mol 
pteroylmonoglutamic acid. 
All data are expressed as means with their 95% confidence intervals. The differences 
in pteroylmonoglutamic acid absorption with and without FeSO, were determined by 
ANOVA. The analysis was performed using Mystat (Systat Inc., Evanston, IL, USA). 
For the in vivo studies the urethane, Bis-Tris, FeSO, and pteroylmonoglutamic acid were 
obtained from Sigma Chemical Company (St. Louis, MO, USA). For the in vitro 
spectrophotometric studies anhydrous FeCl, was obtained from BDH Chemicals (Toronto, 
Ontario, Canada), the DMSO (spectrophotometric grade) was obtained from Mallinckrodt 
(Paris, KY, USA), Fe(NH,),(SO,), was obtained from Fisher Chemical Company (Fair 
Lawn, NJ, USA), and the pteroylmonoglutamic acid was obtained from Aldrich Chemical 
Company (Milwaukee, W1, USA). The [14C]polyethylene glycol 4000 (2.22 GBq/mmol) and 
the [3H]pteroylmonoglutamic acid (1 180-962 GBq/mmol) were supplied by Amersham 
Canada Limited (Oakville, Ontario, Canada). 
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Fig. 2. (A) Spectrophotometric titration of FeCI, with pteroylmonoglutamate in dimethylsulphoxide (DMSO) 
alone. The FeCI, was maintained constant at 0 5  mmol/l, and the pteroylmonoglutamate: Fe3+ratio was increased 
by increasing the concentration of pteroylmonoglutamate. The break in the plot at 1.51 (SE0.22) indicates 
formation of what is most likely a 2: 1 (pteroylmonoglutamate:Fe3+) complex. (B) The legend and conditions are 
as above, except that pteroylmonoglutamic acid was used instead of pteroylmonoglutamate, and the solvent was 
DMSO-aqueous Bis-Tns buffer (4: 1 ,  v/v; pH 6.0). The lack of any well-defined break in the plot indicates no 
observable complex formation occurs. 
RESULTS 
The average rates of pteroylmonoglutamic acid absorption (mean ; 95 YO confidence 
interval) were similar in the absence of FeSO, (95  ; 7 . 6 1  1-4 pmol/cm per min) and in the 
presence of FeSO, at 0.143 mmol/l (10.2; 8-412.0 pmol/cm per rnin), 1-43 mmol/l (9.2; 
74-106 pmol/cm per min) and 6-7 mmol/l (9.6; 7.1-12.1 pmol/cm per min). 
The in vivo stability of pteroylmonoglutamic acid was assessed by HPLC. Before 
perfusion, 96 % of the injected radioactivity eluted in a single peak in the fractions collected 
between 4 and 6 min. In animals perfused with buffer containing pteroylmonoglutamic acid 
but no Fe, pteroylmonoglutamic acid was 93 YO stable. In two animals perfused with 0.143, 
1.43 and 6 7  mmol FeSO,/l, pteroylmonoglutamic acid was 100,84 and 100 YO stable in vivo 
respectively. 
The addition of FeCl, to pteroylmonoglutamate (prepared by adding 1 mol NaOH/mol 
pteroylmonoglutamic acid) resulted in the formation of a reddish precipitate. The spectrum 
of this precipitate (not shown) had a shoulder at 475 nm, similar to that shown in Fig. 1 (A), 
and is probably due to an Fe3+-pteroylmonoglutamate complex. To avoid experimental 
problems associated with characterizing this precipitate, spectrophotometric experiments 
were carried out in DMSO. Since pteroylmonoglutamic acid is soluble in DMSO, the 
formation of its complex with Fe can be more easily characterized spectrophotometrically. 
Thus, under these conditions the relative strength of binding and the stoichiometry of the 
complex formation can be more easily obtained. Upon the addition of anhydrous FeC1, in 
DMSO to pteroylmonoglutamate in DMSO, a new spectrum was obtained that exhibited 
a shoulder at 475 nm (Fig. 1 (A)). This new shoulder, which was not present in either 
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Fig. 3. The visible spectrum of 05 mmol ferrous ammonium sulphate/l and 1-0 mmol pteroylmonoglutamate/l in 
dimethylsulphoxide alone. The new shoulder at 575 nm is indicative of a Fez+-pteroylmonoglutamate complex. 
The absorbance at 575 nm decreased with time due to the oxidation of Fe'+-pteroylmonoglutamate. The spectra 
were recorded at 0.5, 2.5, 4.5 and 305 min respectively. 
pteroylmonoglutamate or FeCl, (Fig. 1 (A)), is indicative of complex formation between 
Fe3+ and pteroylmonoglutamate. A spectrophotometric titration (Fig. 2(A)) in DMSO 
only gave a plot with two straight line segments that intersected at 1.51 ( ~ ~ 0 . 2 2 ) m o l  
pteroylmonoglutamic acid/mol Fe3+. This result probably indicates that formation of a 2 : 1 
complex is occurring as was previously reported (Albert, 1953; Roos & Williams, 1977). A 
small amount of precipitate was seen following complex formation even in DMSO only and 
this may have led to an intersection point that was less than 2: 1. However, in 
DMSO-aqueous Bis-Tris buffer (4: 1 ,  v/v; pH 6.0) there was no spectroscopic evidence for 
complex formation (Fig. 1 (B)). Also a spectrophotometric titration (Fig. 2(B)) gave no 
well-defined intersection point. The increase in absorbance seen with increasing 
pteroylmonoglutamic acid : Fe3+ molar ratio is due to pteroylmonoglutamic acid alone. 
Thus at lower pH, corresponding to that whch might be obtained in vivo, no evidence for 
complex formation was obtained. Spectroscopic evidence for complex formation between 
Fez+ and pteroylmonoglutamate was also seen (Fig. 3). When pteroylmonoglutamate was 
mixed with Fez+ in DMSO only, a spectrum with a new shoulder at 575 nm was observed. 
The absorbance of 575 nm decreased with time probably corresponding to air-oxidation of 
Fe2+ to FeS+. However, in DMSO-buffer (4 : 1, v/v; pH 6-0), no spectroscopic evidence was 
found for the formation of an Fez+-pteroylmonoglutamic acid complex. 
DISCUSSION 
In the present study we have shown that both Fez+ and Fe3+ ions can form a complex with 
pteroylmonoglutamic acid. However, complex formation could only be seen in DMSO 
alone or in aqueous solution under basic conditions when a precipitate of the complex was 
observed to form with the pteroylmonoglutamate anionic species. However, under more 
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physiological conditions in DMSO-aqueous buffer (pH 6.0), with a pH that more closely 
approximates that found in the gastrointestinal tract, no spectroscopic evidence was found 
for complex formation with either Fe3+ or Fez+ ions. Thus, the lack of effect of CO- 
administration of FeSO, on the absorption of pteroylmonoglutamic acid in the rat is 
probably due to the low binding ability of Fe with pteroylmonoglutamic acid under 
physiological conditions. This observation is important for several reasons. Fe preparations 
reduce the absorption of many compounds which bind Fe (Campbell & Hasinoff, 1991; 
Campbell et al. 1992a, b). Pteroylmonoglutamic acid and Fe are frequently supplemented 
in pregnant woman to reduce the incidence of neural tube defects (Czeizel & Dudas, 1992) 
and Fe deficiency respectively. A reduction in pteroylmonoglutamic acid absorption could 
therefore have serious consequences during pregnancy. Pteroylmonoglutamic acid is also 
supplemented in patients with anaemia secondary to pteroylmonoglutamic acid deficiency 
and an Fe interaction reducing pteroylmonoglutamic acid absorption could adversely affect 
patients treated with both agents. Finally, the combination of pteroylmonoglutamic acid 
with Fe salts in a tablet would be irrational if Fe salts caused substantial reductions in 
pteroylmonoglutamic acid absorption. 
This animal model has been used to demonstrate a significant Feecimetidine interaction 
and a nonsignificant interaction between FeSO, and phenytoin (Campbell et al. 1993a, b). 
As this model overestimated the extent of the cimetidine-FeSO, interaction relative to 
results obtained in humans (Partlow et al. 1993), it is unlikely there will be a clinically 
important interaction between FeSO, and pteroylmonoglutamic acid in humans. 
Pteroylmonoglutamic acid and the pteroylmonoglutamic acid : Fe complex have several 
characteristics suggested to favour Fe reducing pteroylmonoglutamic acid absorption 
(Campbell & Hasinoff, 1991). The pteroylmonoglutamic acid: Fe complex is poorly soluble 
even in DMSO alone. Precipitation of complexes is likely to contribute to reduced 
bioavailability (Campbell & Hasinoff, 1991). Further, not only is Fe formulated in the same 
tablet as pteroylmonoglutamic acid but the high molar ratio of Fe : pteroylmonoglutamic 
acid in most formulations strongly favours binding of pteroylmonoglutamic acid (Campbell 
& Hasinoff, 1991). The results of the present study are consistent with the hypothesis that 
the strength of the Fe complex formation is a major determinant of whether a significant 
Fe interaction will occur (Campbell & Hasinoff, 1991). Even in the presence of other factors 
favouring interaction it appears that the log stability constant of the complex must be 
higher than 7.9 before a substantial interaction will occur. Fe can also catalyse oxidation 
and reduction reactions, irreversibly altering compounds (Campbell & Hasinoff, 199 1). 
However, the chemical stability of pteroylmonoglutamic acid in the presence of Fe ions is 
also against a demonstrable interaction reducing pteroylmonoglutamic acid absorption. 
We could not demonstrate a significant effect of FeSO, on pteroylmonoglutamic acid 
absorption in an animal model demonstrated to be sensitive to the presence of Fe 
interactions (Campbell et al. 1 9 9 3 ~ ;  Partlow et al. 1993). Further, we could not find 
evidence of a significant chemical interaction between pteroylmonoglutamic acid and Fe 
ions even in a partially aqueous solution. It is unlikely that concurrent ingestion of 
pteroylmonoglutamic acid with FeSO, or the inclusion of pteroylmonoglutamic acid with 
Fe salts in a tablet will significantly reduce pteroylmonoglutamic acid absorption. 
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